FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103403740> ?p ?o ?g. }

• W2103403740 endingPage "338" @default.
• W2103403740 startingPage "330" @default.
• W2103403740 abstract "The prognostic utility of vascular endothelial growth factor A (VEGF-A) splice variants in patients with advanced breast cancer treated with bevacizumab has not been studied.A total of 111 patients with metastatic breast cancer treated with weekly docetaxel or ixabepilone without bevacizumab (cohort A) and 100 treated with weekly paclitaxel and bevacizumab (cohort B) were studied. Formalin-fixed tumors were macrodissected for reverse transcription quantitative polymerase chain reaction relative quantification of VEGF-A165, -189, and -206 isoforms spliced at exon 8 proximal splice site (VEGF-Axxxa) and at exon 8 distal splice site (VEGF-Axxxb).For high VEGF-Axxxa, the hazard ratios (HRs) for progression were 1.08 (P = .71) in non-bevacizumab-treated patients (cohort A) and 0.66 (P = .22) in bevacizumab-treated patients (cohort B), and the HRs for death were 1.45 (P = .13) and 0.50 (P = .049), respectively. The interaction of VEGF-Axxxa with bevacizumab administration was significant (P = .011) for overall survival (OS). High tissue VEGF-Axxxb was not prognostic in cohort A but was predictive for bevacizumab benefit in cohort B (HR for progression, 0.57 [P = .04]; HR for death, 0.51 [P = .02]). Exploratory analyses done only in cohort B suggested that abundance of VEGFR1 messenger RNA (mRNA) in peripheral blood and low VEGFR2 mRNA in tissue correlated with poor outcome. In multivariate analysis, high tissue mRNA of angiogenic VEGF-Axxxa in the presence of bevacizumab therapy predicted for favorable progression-free survival (HR for progression, 0.39; P = .0227) and OS (HR for death, 0.32; P = .0140).Tissue mRNA expression of angiogenic VEGF-Axxxa isoforms was retrospectively associated with adverse prognosis in the absence of bevacizumab and with favorable outcome when bevacizumab was administered in patients with advanced breast cancer." @default.
• W2103403740 created "2016-06-24" @default.
• W2103403740 creator A5005730021 @default.
• W2103403740 creator A5012112204 @default.
• W2103403740 creator A5012784345 @default.
• W2103403740 creator A5015437737 @default.
• W2103403740 creator A5020996278 @default.
• W2103403740 creator A5022230385 @default.
• W2103403740 creator A5027646786 @default.
• W2103403740 creator A5032663338 @default.
• W2103403740 creator A5033573338 @default.
• W2103403740 creator A5046758725 @default.
• W2103403740 creator A5047656028 @default.
• W2103403740 creator A5051365519 @default.
• W2103403740 creator A5060298984 @default.
• W2103403740 date "2014-10-01" @default.
• W2103403740 modified "2023-10-16" @default.
• W2103403740 title "Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer" @default.
• W2103403740 cites W1573363574 @default.
• W2103403740 cites W1968449590 @default.
• W2103403740 cites W1970578871 @default.
• W2103403740 cites W1976221241 @default.
• W2103403740 cites W1992112921 @default.
• W2103403740 cites W1993040477 @default.
• W2103403740 cites W2005825076 @default.
• W2103403740 cites W2007087942 @default.
• W2103403740 cites W2007136227 @default.
• W2103403740 cites W2033578818 @default.
• W2103403740 cites W2061805653 @default.
• W2103403740 cites W2065863629 @default.
• W2103403740 cites W2067020920 @default.
• W2103403740 cites W2070264012 @default.
• W2103403740 cites W2077129920 @default.
• W2103403740 cites W2082910811 @default.
• W2103403740 cites W2095545927 @default.
• W2103403740 cites W2099387131 @default.
• W2103403740 cites W2103563357 @default.
• W2103403740 cites W2109491042 @default.
• W2103403740 cites W2111391096 @default.
• W2103403740 cites W2115113482 @default.
• W2103403740 cites W2116277547 @default.
• W2103403740 cites W2120642503 @default.
• W2103403740 cites W2147461659 @default.
• W2103403740 cites W2152414695 @default.
• W2103403740 cites W2154670252 @default.
• W2103403740 cites W2163814095 @default.
• W2103403740 cites W2164971856 @default.
• W2103403740 cites W2170226272 @default.
• W2103403740 cites W4235333461 @default.
• W2103403740 cites W4239593130 @default.
• W2103403740 doi "https://doi.org/10.1016/j.clbc.2014.02.009" @default.
• W2103403740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24703319" @default.
• W2103403740 hasPublicationYear "2014" @default.
• W2103403740 type Work @default.
• W2103403740 sameAs 2103403740 @default.
• W2103403740 citedByCount "10" @default.
• W2103403740 countsByYear W21034037402015 @default.
• W2103403740 countsByYear W21034037402016 @default.
• W2103403740 countsByYear W21034037402017 @default.
• W2103403740 countsByYear W21034037402018 @default.
• W2103403740 countsByYear W21034037402019 @default.
• W2103403740 countsByYear W21034037402020 @default.
• W2103403740 countsByYear W21034037402022 @default.
• W2103403740 countsByYear W21034037402023 @default.
• W2103403740 crossrefType "journal-article" @default.
• W2103403740 hasAuthorship W2103403740A5005730021 @default.
• W2103403740 hasAuthorship W2103403740A5012112204 @default.
• W2103403740 hasAuthorship W2103403740A5012784345 @default.
• W2103403740 hasAuthorship W2103403740A5015437737 @default.
• W2103403740 hasAuthorship W2103403740A5020996278 @default.
• W2103403740 hasAuthorship W2103403740A5022230385 @default.
• W2103403740 hasAuthorship W2103403740A5027646786 @default.
• W2103403740 hasAuthorship W2103403740A5032663338 @default.
• W2103403740 hasAuthorship W2103403740A5033573338 @default.
• W2103403740 hasAuthorship W2103403740A5046758725 @default.
• W2103403740 hasAuthorship W2103403740A5047656028 @default.
• W2103403740 hasAuthorship W2103403740A5051365519 @default.
• W2103403740 hasAuthorship W2103403740A5060298984 @default.
• W2103403740 hasConcept C121608353 @default.
• W2103403740 hasConcept C126322002 @default.
• W2103403740 hasConcept C142724271 @default.
• W2103403740 hasConcept C143998085 @default.
• W2103403740 hasConcept C167734588 @default.
• W2103403740 hasConcept C207103383 @default.
• W2103403740 hasConcept C2775930923 @default.
• W2103403740 hasConcept C2776694085 @default.
• W2103403740 hasConcept C2777025900 @default.
• W2103403740 hasConcept C2777802072 @default.
• W2103403740 hasConcept C2781190966 @default.
• W2103403740 hasConcept C44249647 @default.
• W2103403740 hasConcept C530470458 @default.
• W2103403740 hasConcept C71924100 @default.
• W2103403740 hasConcept C72563966 @default.
• W2103403740 hasConcept C90924648 @default.
• W2103403740 hasConceptScore W2103403740C121608353 @default.
• W2103403740 hasConceptScore W2103403740C126322002 @default.
• W2103403740 hasConceptScore W2103403740C142724271 @default.
• W2103403740 hasConceptScore W2103403740C143998085 @default.

• next